Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) and Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.
Profitability
This table compares Lakefront Biotherapeutics American Depositary Shares and Fulcrum Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lakefront Biotherapeutics American Depositary Shares | N/A | N/A | N/A |
| Fulcrum Therapeutics | N/A | -25.38% | -24.15% |
Volatility and Risk
Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.59, indicating that its stock price is 159% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lakefront Biotherapeutics American Depositary Shares | 0 | 7 | 1 | 1 | 2.33 |
| Fulcrum Therapeutics | 4 | 7 | 1 | 0 | 1.75 |
Lakefront Biotherapeutics American Depositary Shares presently has a consensus price target of $30.67, suggesting a potential upside of 7.64%. Fulcrum Therapeutics has a consensus price target of $8.20, suggesting a potential upside of 112.99%. Given Fulcrum Therapeutics’ higher probable upside, analysts plainly believe Fulcrum Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.
Institutional & Insider Ownership
32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Lakefront Biotherapeutics American Depositary Shares and Fulcrum Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lakefront Biotherapeutics American Depositary Shares | $1.26 billion | 1.49 | $363.05 million | ($1.41) | -20.21 |
| Fulcrum Therapeutics | $80.00 million | 3.67 | -$74.88 million | ($1.21) | -3.18 |
Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Fulcrum Therapeutics. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Fulcrum Therapeutics beats Lakefront Biotherapeutics American Depositary Shares on 7 of the 13 factors compared between the two stocks.
About Lakefront Biotherapeutics American Depositary Shares
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Lakefront Biotherapeutics American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakefront Biotherapeutics American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
